ARTICLE | Top Story
EMEA requires data from MLNM/ILXO
March 30, 2001 8:00 AM UTC
The EMEA's Committee on Proprietary Medicinal Products (CPMP) recommended approval "under exceptional circumstances" of MLNM and ILXO's MabCampath alemtuzumab humanized monoclonal antibody against CD5...